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Abstract
Background: Both mechanistic features and recent correlative findings suggest a potential role
for protein kinase C-beta (PKC-β) in tumor pathogenesis, particularly in B-cell malignancies. To
evaluate the role of this gene in lymphoid malignancies, we analyzed global gene expression data to
quantify PKC-β expression across diagnostic groups and, when possible, determined correlations
between PKC-β expression and survival.
Results:  Our analysis showed that the level of PKC-β expression was highest in chronic
lymphocytic leukemia and follicular lymphoma. Within diffuse large-B cell lymphoma (DLBCL),
PKC-β expression was significantly higher in activated B-cell- like subtype than germinal center B-
cell- like subtype (P < 0.0001). Elevated PKC-β appeared to be associated with worse survival in
both of these subtypes. When analyzed within clinically defined risk groups established by the
International Prognostic Index (IPI), PKC-β expression was lowest in patients with low IPI scores
(0–1). Within intermediate- and high-risk IPI groups, elevated PKC-β expression was associated
with worse survival, suggesting that PKC-β may expand the prognostic value of the IPI. Results of
global gene expression analyses of DLBCL samples corroborate previous observations that anti-
apoptosis, cell proliferation, and B-cell proliferation signaling pathways are functionally related to
PKC-β.
Conclusion: We present a first detailed pharmacogenomics report comparing PKC-β mRNA
expression across different lymphoid malignancies and evaluating it as an outcome predictor. Our
findings suggest that DLBCL patients with elevated PKC-β have a worse prognosis, indicating that
further evaluation of PKC-β as a chemotherapeutic target for lymphoid malignancies is warranted.
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Background
The protein kinase C (PKC) family of serine/threonine
kinases has an important role in biological processes
related to signal transduction, cell proliferation, and
apoptosis. The PKC-β 1 and 2 isoforms? have been impli-
cated in several biological pathways and could serve as tar-
gets for cancer chemotherapy [1,2].
Protein kinase C-beta (PKC-β) is a regulator of the vascu-
lar endothelial growth factor (VEGF) signal cascade and
angiogenesis [3-7]. Xia et al demonstrated that PKC inhib-
itors could block VEGF-induced PKC activation and
endothelial cell proliferation [7]. Additionally, VEGF-
mediated mitogenic effects were blocked by PKC-β inhib-
itor, LY333531, but not by antisense oligonucleotides to
PKC-α [7].
PKC-β is a key component of the B-cell receptor (BCR) sig-
naling pathway and is clearly involved in the normal func-
tion of B-cells. PKC-β knockout mice have impaired
humoral and B-cell proliferative responses [8]. BCR stim-
ulation of PKC-β-deficient B cells failed to up-regulate the
anti-apoptotic protein Bcl-xl, and quenched cell survival
signals [9]. Likewise, in intact B cells, PKC-β activation
downstream of BCR antigen binding results in immature
B-cell proliferation and survival [10]. PKC-β inhibitors
reduced the cell viability of two diffuse large B-cell lym-
phoma (DLBCL) cell lines, SUDHL6 and OCILY10, that
have over-expressed PKC-β [9]. The PKC-β inhibitor
enzastaurin has shown activity in xenograft mouse mod-
els of diffuse large cell lymphoma [11].
These findings suggest that PKC-β likely performs a piv-
otal role in the pathogenesis of malignant B cells. Shipp et
al used gene expression profiling and supervised learning
methods with newly diagnosed DLBCL samples to iden-
tify genes that were differentially expressed in fatal/refrac-
tory versus cured subgroups [12]. Their analysis produced
a multi-gene outcome prediction model that provided
unique information not represented in the existing clini-
cal prognostic model. From this study it was determined
that PKC-β was one of the most prominently over-
expressed genes in fatal/refractory DLBCL patients (n =
58; P = 0.03). Shipp et al also reported that PKC-β protein
expression was positively associated with transcript abun-
dance and closely associated with clinical outcome in a
pilot series of DLBCL patients (n = 21; P = 0.03).
The availability of microarray gene expression databases
in the public domain provides a potentially valuable
resource for the identification of critical pathways in can-
cer treatment. In this retrospective analysis, we examined
microarray gene expression databases to determine if
PKC-β expression was elevated in various types of lym-
phoid malignancies. We also examined whether elevated
PKC-β expression was associated with worse survival in
DLBCL and its subtypes. We evaluated PKC-β to deter-
mine whether it could predict survival within the clini-
cally defined risk groups established by the International
Prognostic Index (IPI) [13]. To validate the biological rel-
evance of these findings, we evaluated other genes repre-
sented on the arrays to identify gene pathways that might
be coordinately regulated with PKC-β.
Results
PKC-β expression in lymphoid malignancies
Lymphoma is the fifth most common cancer in the
United States and represents over forty subtypes of cancers
arising within the lymphatic system. Lymphomas are clas-
sified into several large groups by cell type: the B cell
tumors, the T cell and natural killer cell tumors, Hodgkin
lymphoma, and other minor groups. The most prevalent
subtypes include DLBCL, chronic lymphocytic leukemia
(CLL), follicular lymphoma (FL), and Mantel cell lym-
phoma (MCL). Our analysis of PKC-β gene expression
across lymphoma subtypes [14] revealed that PKC-β
expression was highest in CLL, notably 3-fold greater than
in normal lymphoid (NL) samples (CLL vs NL, P  <
0.0001; Fig 1). Follicular lymphoma cases exhibited
higher PKC-β expression than DLBCL cases (P < 0.0001).
Analysis of a second dataset derived from Affymetrix
arrays [12] showed a similar trend (data not shown) with
mean PKC-β expression significantly elevated in FL rela-
tive to DLBCL samples (P = 0.018).
PKC-β as an outcome predictor in DLBCL
To determine the relationship between PKC-β expression
and survival for DLBCL patients, we analyzed three micro-
array datasets (Table 1). In the Rosenwald et al dataset
[15], patients with high PKC-β expression (quartile 4)
were disproportionately represented among the three
PKC-β expression in lymphoma subtypes and normal tissues Figure 1
PKC-β expression in lymphoma subtypes and normal 
tissues. Mean PKC-β (isoform 2) gene expression in CLL, 
DLBCL, FL, hematopoetic cell lines, and normal lymphoid 
(NL) tissues. Vertical error bars represent standard devia-
tions for each category.
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gene expression DLBCL subtypes: germinal center B-cell-
like (GCB), activated B-cell- like (ABC), and type 3 (Fig 2).
Seventy-five percent (45/60) of the lowest PKC-β-express-
ing patients (quartile 1) belonged to the GCB subtype
(DLBCL subtype with the best long-term prognosis). In
contrast, 63% (37/59) of the highest PKC-β-expressing
patients (quartile 4) belonged to the ABC subtype, which
is characterized by a lower 5-year survival rate. Lympho-
mas classified as ABC had significantly higher mean PKC-
β expression than either type 3 (43% higher, P = 0.0011)
or GCB (76% higher, P < 0.0001).
Kaplan-Meier estimates [16] of 237 DLBCL patients
showed a negative association between PKC-β gene
expression and median survival time (Fig 3A; P = 0.0129).
Patients with very high PKC-β expression (quartile 4) had
a median survival time of 1.9 years, whereas patients with
low PKC-β expression (quartile 1) had a median survival
time of 10.6 years. Our analysis of expression data for 58
DLBCL samples from Shipp et al [12] showed that
patients with high PKC-β expression had shorter survival
than patients with low or medium PKC-β expression (Fig
3B;  P  = 0.0126). The association between high PKC-β
expression and poor survival indicated in Kaplan-Meier
analysis is also confirmed by an alternative approach
using the Cox Proportional-Hazards Regression model
(data not shown). Applying similar analyses to the Aliza-
deh et al dataset [14] showed no statistically significant
association between high PKC-β expression and overall
survival, possibly due to a relatively small sample size.
We further analyzed data from Rosenwald et al [15] to
determine if PKC-β-defined subgroups differed with
respect to median survival times within the DLBCL sub-
types ABC, GCB, and type 3 (Fig 4). To establish larger
subgroups for more robust comparisons, we combined
quartiles 1 and 2 and then combined quartiles 3 and 4.
Observed differences in survival between these PKC-β
defined subgroups were not statistically significant but
trends were consistent with previous analyses.
Comparison of a PKC-β-defined outcome predictor and 
the IPI
Each of the PKC-β defined quartiles were fairly evenly rep-
resented in each of the three IPI risk groups for the Rosen-
wald dataset [15] (low, intermediate, and high) (Fig 5A).
Patients with high PKC-β expression (quartiles 3 and 4)
were not overrepresented in the IPI high-risk group. In
fact, 57.5% of these patients (61 of 106 patients in quar-
tiles 3 + 4) were categorized as IPI intermediate-risk. PKC-
β expression differed significantly across IPI risk groups
(ANOVA P = 0.008). PKC-β expression was significantly
higher in IPI intermediate-risk patients than in IPI low-
risk patients (1.4-fold difference; P = 0.0005). Patients in
IPI intermediate- and high-risk subgroups who also had
high PKC-β expression (quartiles 3 + 4) showed worse sur-
vival (Fig 5B). In the intermediate-risk group, patients
with high PKC-β expression had significantly shorter
median survival times than patients with lower PKC-β
expression (quartile 3 + 4 = 1.9 years vs quartiles 1 + 2 = 6
years, P = 0.013).
Genes differentially expressed in PKC-β-defined subgroups
We examined gene expression data for all genes on the
cDNA arrays first analyzed by Rosenwald et al [15] to fur-
ther validate the biologic relevance of PKC-β as a potential
prognostic marker for patients with DLBCL. We identified
820 cDNA clones that were differentially expressed
between the highest (quartile 4) and the lowest (quartile
1) PKC-β subgroups. Eighty-one percent (664/820) of
these clones showed higher expression in quartile 4 than
quartile 1, suggesting that they may be functionally
related to PKC-β (Fig 6, Table 3). These over-expressed
clones were mapped to 345 unique UniGene clusters,
with approximately 60% having Gene Ontology annota-
tions that can be linked to related biological processes and
pathways. Many of these genes are represented in anti-
apoptosis, cell proliferation, B-cell signaling, cell-cycle
control, and DNA repair pathways, further confirming the
link between PKC-β activation and tumor growth (Table
3, and Additional file 1). Many genes involved in replica-
tion, transcription, and translation are also up-regulated,
possibly reflecting the high rate of cell proliferation in
these patients.
The distribution of patients in each PKC-β-defined quartile  among DLBCL subtypes Figure 2
The distribution of patients in each PKC-β-defined 
quartile among DLBCL subtypes. DLBCL subtypes 
included GCB, ABC, and type 3 as defined by Rosenwald et 
al (2002). Samples were ordered according to relative 
expression of PKC-β and assigned to a quartile such that 
patients with the highest PKC-β expression were repre-
sented in quartile 4.
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Discussion
When validating any gene or gene product as a viable tar-
get for cancer chemotherapy, it is important to move
beyond in vitro models and understand how the target
gene expression affects disease progression and how it var-
ies in patient populations. Global gene expression analy-
sis with DNA microarray technology has proven to be a
useful tool for target identification and validation in both
the preclinical and clinical settings. Gene expression anal-
ysis is currently used for diagnosis, prognosis, and thera-
peutic decision-making in a variety of cancers.
Retrospective analysis of public microarray data associ-
ated with clinical studies in primary cancers allows us to
evaluate potential targets, and validate their prognostic
significance across larger patient populations and more
tumor types. Analyzing microarray gene expression data
in publicly available database is a valuable approach to
generate novel findings using the existing data. Here, we
present the first detailed pharmacogenomics report com-
paring PKC-β mRNA expression across different lymphoid
malignancies and evaluating it as an outcome predictor.
Our analysis of PKC-β across different diagnostic catego-
ries revealed significantly higher expression in CLL
patients as compared to normal lymphoid tissues (Fig 1).
When the expression of a potential drug target is higher in
tumor cells than in normal cells, there is an implication
that the tumor cell requires that target for its survival;
thus, it follows that blocking the target would impede can-
cer cell proliferation. Elevated expression of PKC-β in FL
relative to DLBCL suggests that PKC-β could be important
to the pathogenesis of FL. A correlation between PKC-β
expression and survival in CLL and FL patients would fur-
ther establish the importance of PKC-β as a viable target
for cancer chemotherapy. Although this line of investiga-
tion is of considerable interest, these analyses were not
done due to the lack of clinical information accompany-
ing gene expression data.
Correlation between PKC-β gene expression and patient survival in DLBCL Figure 3
Correlation between PKC-β gene expression and patient survival in DLBCL. DLBCL patients in two datasets (A: 
Rosenwald et al, 237 samples; B: Shipp et al, 58 samples) were separated into four and three groups with an equal number of 
samples in each group, respectively, based on PKC-β gene expression. Higher quartiles represent groups with higher PKC-β 
expression. Kaplan-Meier survival curves are shown for each group. Median survival (MS) times are shown when sufficient data 
were available for each group.
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Table 1: Gene expression datasets included in this study
Reference Cancer type Array platform Sample size URL for data downloading
Alizadeh et al (2000) DLBCL, CLL, FL cDNA (Lymphochip) 102 http://www.ncbi.nlm.nih.gov/geo/
Shipp et al (2002) DLBCL, FL Affymetrix (HU6800) 77 http://www-genome.wi.mit.edu/mpr/lymphoma/
Rosenwald et al (2002) DLBCL cDNA (Lymphochip) 240 http://llmpp.nih.gov/Biology Direct 2007, 2:8 http://www.biology-direct.com/content/2/1/8
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An alternative approach to target validation is to discover
genes (or gene products) as potential drug targets that are
elevated in a subset of cancer patients with poor clinical
outcomes. This may be the case with PKC-β in DLBCL.
Each of the two major gene expression profiling studies
that characterized DLBCL samples yielded a multigene
predictive model (17 genes in Rosenwald et al and 13
genes in Shipp et al), but only the 13-gene model pre-
sented by Shipp et al included PKC-β as a negative predic-
tor for survival [12,15]. In fact, there was no overlap
between genes represented in the two models. This dis-
crepancy could, at least in part, be attributed to different
patient populations, different array platforms, and/or dif-
ferent analysis algorithms.
Our analysis of PKC-β expression in the Rosenwald data-
set [15] yielded results consistent with the observations of
Shipp et al [12]. High PKC-β expression was associated
with shorter overall survival time. Our new analysis of the
Shipp dataset showed similar trends. The outcome predic-
tion model applied in Rosenwald et al [15] clustered
DLBCL patients into three subtypes: GCB, ABC, and type
3, on the basis of cell-of-origin gene expression patterns.
Our analysis showed significantly higher PKC-β in the
ABC as compared to the GCB subtype. The biological sig-
nificance of this finding was highlighted by our observa-
tion that within the ABC subtype, high PKC-β-expressing
patients (quartile 3 + 4) appeared to have shorter median
survival times (Fig 4), although the results were not statis-
tically significant. PKC-β expression appears to provide
unique prognostic information that is not reflected in the
cell-of-origin gene signature model for DLBCL. Analysis of
survival curves for PKC-β stratified subgroups within each
IPI risk group revealed equivocal findings (Fig 5B). For the
IPI intermediate-risk group, elevated PKC-β expression
was significantly associated with worse survival, and it
appears that this biomarker may provide unique prognos-
tic information not represented in the clinical prognostic
model. A similar trend but statistically insignificant was
evident with IPI high-risk patients, but there was no asso-
ciation for the IPI low-risk group. This lack of significance
may be a sample size limitation, but other factors may
also be important. Perhaps additional genetic biomarkers
or clinical measures could be combined with PKC-β to
improve predictive power and to better characterize the
relative risks for patients in the IPI low- or high-risk
groups.
Our observations with DLBCL patients reinforce previous
findings that PKC-β gene expression likely contributes to
the pathological processes associated with DLBCL. These
findings are complimented by a number of studies that
used tissue arrays to demonstrate an association between
increased PKC-β protein expression and shorter 5-year
disease-free survival [12,17,18]. Similarly, Hans et al [19]
applied multivariate analysis to tissue array data and
showed that patients who expressed either PKC-β or cyclin
D2 had a 5-year overall survival of 30% compared with
52% for patients who were negative for both markers.
Gene annotation and pathway analyses presented in the
current report illustrated that genes in anti-apoptosis, cell
Kaplan-Meier plots of overall survival for GCB, ABC, and type 3 DLBCL Figure 4
Kaplan-Meier plots of overall survival for GCB, ABC, and type 3 DLBCL. Subtypes were stratified according PKC-β 
expression. Quartile 1 was combined with quartile 2 and quartile 3 was combined with quartile 4 to allow for more robust 
comparisons. Higher quartiles represent groups with higher PKC-β expression.
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proliferation, B-cell proliferation/differentiation, cell-
cycle control, and DNA repair pathways are over-
expressed in PKC-β-defined quartile 4 (Table 3, and Addi-
tional file 1). We observed elevated expression of ribos-
omal protein S6 kinase, phosphoinositide-3-kinase, and
transforming growth factor β in high PKC-β expressors,
supporting the notion of cross-talk among these signaling
pathways [20,21]. Up-regulation of these pathways inhib-
its B-cell apoptosis and facilitates cell proliferation. These
results confirm that PKC-β is clinically important to BCR
signaling. Genes identified in this analysis may, after fur-
ther research, prove to be important as functional biomar-
kers of PKC-β inhibition. Additionally, these findings may
direct us to other signaling pathways and specific genes
therein that are potential targets for cancer chemotherapy.
Conclusion
Data mining, as presented here, provides an integrated
approach to target assessment and validation for drug dis-
covery and development. Our analysis showed that for
DLBCL patients, elevated PKC-β expression was associ-
ated with worse survival. Previously defined DLBCL sub-
groups characterized by decreased survival (e.g. ABC and
type 3 DLBCL) also had elevated PKC-β expression. Addi-
tional studies aimed at validating this target in DLBCL
patients are warranted and should include patients that
Relationship between PKC-β gene expression as an outcome predictor and the international prognostic index (IPI) Figure 5
Relationship between PKC-β gene expression as an outcome predictor and the international prognostic index 
(IPI). The IPI classifies patients into 3 risk groups: low-risk, defined by an IPI score of 0–1; intermediate-risk, defined by an IPI 
score of 2–3; and high-risk, defined by an IPI score of 4–5. IPI scores were unknown for 18 patients. A. Number of patients 
represented in each PKC-β defined quartile for the IPI low-, intermediate-, and high-risk subgroups. B. Kaplan-Meier plots of 
overall survival for IPI low-, intermediate-, and high-risk subgroups, stratified according to the quartile of PKC-β expression. 
Quartile 1 was combined with quartile 2 and quartile 3 was combined with quartile 4 to allow for more robust comparisons. 
Higher quartiles represent groups with higher PKC-β expression.
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would now typically receive rituximab as part of their
therapeutic regimen. PKC-β is also significantly elevated
in CLL and FL. Information is still needed to determine
whether the trend observed in DLBCL between high PKC-
β expression and poor survival is mirrored in these can-
cers. Taken together, these findings further strengthen pre-
vious assertions that this gene could likely be an
important target for cancer chemotherapy.
Methods
For all analyses, we used gene expression data and corre-
sponding clinical information available on the internet
(Table 1).
Analyses of PKC-β expression in lymphoid malignancies
We assessed PKC-β gene expression in different lym-
phoma subtypes by analyzing data from Alizadeh et al of
102 samples of DLBCL, CLL, FL, hematopoetic cell lines,
and subsets of NL tissues [14]. This gene expression pro-
filing dataset from Lymphochip cDNA arrays, included
genes preferentially expressed in lymphocytes or genes
with known or possible roles in lymphocyte differentia-
tion and proliferation under normal or malignant condi-
tions. We focused on data representing PKC-β isoform 2
here, but analyses of PKC-β isoform 1 clones yielded sim-
ilar results.
Table 3: Categories of genes over-expressed in the highest PKC-β 
expressing (quartile 4) DLBCL patients
Anti-apoptosis
Signaling in B-cell proliferation, differentiation
Cancer development
Cell proliferation/cell-cycle control
DNA repair
DNA, RNA, protein synthesis
Genes differentially expressed in high versus low PKC-β expressing DLBCL patients (quartile 4 vs quartile 1) Figure 6
Genes differentially expressed in high versus low PKC-β expressing DLBCL patients (quartile 4 vs quartile 1). 
Gene expression level is represented by log transformed ratios of hybridization signal from experimental samples versus the 
reference sample. Expression is shown in colors, with red representing high expression and green representing low expres-
sion. 820 cDNA clones were differentially expressed (FDR < 0.01 and missing data points < 40) between the PKC-β defined 
quartile 4 and 1. 81% of these genes were over-expressed in the highest PKC-β subgroup (quartile 4).
PKC-β Quartile 1 PKC-β Quartile 4
-1.5 1.5
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Using a second dataset, first reported by Shipp et al, we
assessed PKC-β expression in 58 DLBCL and 19 FL sam-
ples [12]. Affymetrix HU6800 was the microarray plat-
form (Affymetrix, Santa Clara, CA). We analyzed results
from two probesets representing PKC-β: X06318_at (PKC-
β isoform 1) and X07109_at (PKC-β isoform 2). Expres-
sion data reported as average difference were generated by
Affymetrix MAS 4.0. Expression data from X06318_at and
X07109_at were highly correlated (Pearson's correlation
coefficient R = 0.82); therefore, only data from one
probeset, X07109_at, are presented.
Analyses of PKC-β as an outcome predictor in DLBCL and 
DLBCL subtypes
To examine the relationship between PKC-β expression
and survival in DLBCL patients, we analyzed three micro-
array datasets (Table 1). All DLBCL patients evaluated
received anthracycline-based chemotherapy, which usu-
ally consisted of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP).
The most extensive microarray dataset was generated by
Rosenwald et al [15] as part of the Lymphoma/Leukemia
Molecular Profiling Project (LLMPP). Gene expression
analysis was performed on biopsy samples from 240
DLBCL patients using the Lymphochip. A total of six
clones were annotated as PKC-β (Table 2). After analyzing
the sequence of these six clones, we chose 19235 (Gen-
Bank:AA243358, PKC-β isoform 2) and 28417 (Gen-
Bank:AA479102, PKC-β isoform 1) corresponding to the
3'-UTR of PKC-β for further analysis. Nucleic acid
sequences in the 3'-UTR are highly specific and cross
hybridization of 3'-UTR to other genes in the same gene
family on microarrays is minimal. Clones not mapped to
the 3'-UTR of the PKC-β gene (34136, 32251, and 24623)
and those missing a significant amount of data in 240
DLBCL samples (15858) were omitted from further anal-
ysis. Gene expression data for 19235 and 28417 were
strongly correlated (Pearson's correlation coefficient
0.84), and data from clone 19235 are presented. For clone
19235, 237 data points were available from 240 patients.
When analyzing the data from Rosenwald et al [15], we
ordered the lymphoma cases according to relative expres-
sion of PKC-β and assigned each to a quartile in ascending
order so that patients with the highest PKC-β expression
were represented in quartile 4. Quartile 1 included 60
patient samples and quartiles 2–4 each included 59
patient samples. We analyzed the association between
PKC-β expression and patient survival for the entire
DLBCL group and compared PKC-β gene expression
across DLBCL subtypes (GCB, ABC, and type 3) which
were previously defined in the multi-gene prediction
model [15].
As part of their original analysis, Rosenwald et al [15]
showed that the gene signature scores and IPI scores [13]
were independent predictors of survival. We compared
PKC-β gene expression across these IPI groups and ana-
lyzed the association between PKC-β gene expression and
survival within each group.
Using DLBCL gene expression data from Shipp et al [12]
(58 samples), we assigned lymphoma samples to one of
three groups characterized by high, medium, and low
PKC-β expression (subgroup sizes were 20, 19, and 19,
respectively) and evaluated the association between PKC-
β expression and survival. We conducted similar analyses
using data from Alizadeh et al [14] of 35 DLBCL samples
(classified as either high or low PKC-β expressors).
Analyses of genes differentially expressed in PKC-β-
defined subgroups
To determine which genes might be coordinately regu-
lated with PKC-β, we evaluated other genes represented
on the arrays and identified clones that varied signifi-
cantly between the two most extreme PKC-β defined sub-
groups (highest: quartile 4 vs lowest: quartile 1).
Statistical methods
Two-tailed t-tests were used for within-dataset compari-
sons of PKC-β gene expression in different lymphoma
subtypes. Fisher's exact tests (using JMP 5.1) were used to
compare patient counts across DLBCL subtypes (GCB,
ABC, type 3), and across IPI risk groups. One way ANOVA
and Student's t-tests with the Bonferroni multiple com-
parison adjustment were used for pair-wise comparisons
of PKC-β gene expression between DLBCL subtypes and
Table 2: Clones on Lymphochip cDNA arrays representing PKC-β
Clone ID GenBank accession Sequence mapping region Available data points from 240 DLBCL samples*
34136 AI540068 5'-UTR + exon1 229
15858 AA479102 3'-UTR 165
28417 AA479102 3'-UTR 236
32251 AA262174 Intron 225
24623 AA830034 Not mapped to PKC-β 212
19235 AA243358 3'-UTR 237
* Rosenwald et al (2002).Biology Direct 2007, 2:8 http://www.biology-direct.com/content/2/1/8
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IPI risk groups. The Kaplan-Meier method [16] was used
to estimate median survival time and the log-rank test was
used to compare survival rates among DLBCL subtypes
and PKC-β-defined subgroups. Time-to-event analyses
were performed in MedCalc (MedCalc Software, Mari-
akerke, Belgium).
Using a two-sided Student's t-test, we identified genes dif-
ferentially expressed between PKC-β-defined subgroups
(highest vs lowest quartile). To account for multiplicity,
the Benjamini and Hochberg [22] false discovery rate con-
trol (FDR) adjustment was applied as FDR = (P × n)/i, in
which P is the P value from the t-test, n is the total number
of genes, and i is the sorted rank of the P value. Using cri-
teria FDR < 0.01 and missing data points < 40, we identi-
fied cDNA clones that were differentially expressed
between the highest and the lowest PKC-β subgroups.
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Reviewers' comments
Reviewer's report 1
Dr. Pierre Pontarotti, Université d'Aix Marseille, Marseille,
France
The authors perform a retrospective analysis showing that
Diffuse Large B cell lymphoma patients with elevated
expression of protein Kinase C-Beta gene have worse prog-
nosis.
This is an important confirmative result that should be
published.
I like very much the idea of performing retrospective anal-
ysis using available data.
I recommend the authors to make a brief comment on the
state of the art on such approaches and especially in the
case of microarray gene expression databases. I think that
this kind of approach will be more and more used in the
future.
Authors' response
We appreciate the comments. Particularly, we agree with the
reviewer that retrospective analysis of available microarray gene
expression data is a "state of art" approach in biomedical
research to generate novel findings by using the existing data.
As recommended by the reviewer, we added several sentences in
the 1st paragraph of the discussion to emphasize this point.
Reviewer's report 2
Dr. Kateryna Makova, Pennsylvania State University,
Pennsylvania, United States
In this paper the authors show that increased PKC-b
expression in some types of cancers can be correlated with
a shorter survival time after treatment.
Major Criticisms
General:
Authors should highlight the novelty of this study better.
Author's response
We followed the reviewer's advice and highlighted the novelty
in both abstract and the discussion section. For example, we
added the statement "We present a first detailed pharmacoge-
nomics report comparing PKC-β mRNA expression across dif-
ferent lymphoid malignancies and evaluating it as an outcome
predictor" in the abstract.
Results:
1. In general this section could be expanded, in particular
section on gene expression analysis that will be of interest
to genomicists.
Author's response
We agree with reviewer's opinion. Please see below our
responses to each of reviewer's specific suggestions.
2. Readers may be unfamiliar with the lymphoma sub-
types, and so a description of each would be beneficial.
Author's response
We followed the reviewer's advice and added a paragraph at the
beginning of the result section to briefly describe the lymphoma
subtypes.
3. When comparing differentially expressed clones
between quartiles 1 and 4 of PKC-b expression, it would
be useful to compare both quartiles to healthy lymphatic
tissues as a control.
Author's response
We completely agree with reviewer's opinion. However, the
Rosenwald dataset that we analyzed did not include healthy
lymphatic tissues as a control. Therefore, we could not compare
PKC-β expression in DLBCL with that of healthy control tis-
sues.Biology Direct 2007, 2:8 http://www.biology-direct.com/content/2/1/8
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4. There are now protein-protein interaction studies that
can be included in the study to identify the protein part-
ners of the expressed mRNA.
Author's response
We agree with the reviewer that protein-protein interaction
data could provide more insights into the role of PKC-β in
DLBCL. However, the main goal of the current study was to
evaluate PKC-β as a target of B lymphocyte malignancies by
analyzing its expression across subtypes and correlation between
expression and survival, and our results have clearly indicated
that PKC-β could be an important target for B cell lymphoma
chemotherapy. Protein-protein interaction would exceed the
scope of this study.
5. What genes are under-expressed in the quartiles, com-
pared to each other, and compared to healthy tissues?
Author's response
We followed the reviewer's suggestion and analyzed genes
under-expressed in quartile 4(high PKC-β expressors). Unlike
those over-expressed genes, we did not observe specific pathways
with significantly under-expressed genes correlated with high
PKC-β expression.
Discussion:
1. It is a little confusing that the comparison of PKC-b
expression across different kinds of cancers is included at
the beginning of the Discussion section. This seems to jus-
tify further studies of PKC-b in CLL and FL cancers
because it was shown to have potential predictor roles in
DLBCL, even though PKC-b expression is much lower in
DLBCL cancers than either CLL or FL. Maybe this para-
graph should be moved to the end of the section, to main-
tain the focus of the paper on PKC-b expression in DLBCL
cancers.
Author's response
We agree with the reviewer regarding further studies of PKC-β
expression in CLL and FL. However, in the dataset we ana-
lyzed, survival data was not available for CLL and FL for more
detailed analysis of PKC-β in these two subtypes, as indicated
in the 2nd paragraph of the discussion section.
2. The authors claim that, "A similar association was evi-
dent with the IPI high-risk patients, but there was no dis-
cernable trend for the IPI low-risk group." This seems like
a strong statement to make. From 5B, it seems that sur-
vival rates are the same for all expression levels in the IPI
low-risk group, not that there is no discernable trend.
Also, it is difficult to assert that the trend is the same in
both the IPI intermediate and IPI high risk group, espe-
cially with the small sample sizes and insignificant p-
value.
Author's response
We agree with the reviewer and modified the wording in the
sentence to indicate that the association between PKC-β expres-
sion and survival was not statistically significant in the high IPI
group and there is completely lack of association in the low IPI
group.
3. The authors claim that, "These results confirm that
PKC-b is clinically important to BCR signaling." This is
not necessarily true, unless one can show that it is the
upregulation of PKC-b that is causing the other factors to
be up-regulated, and not that PKC-b is just another
byproduct of some other up-regulation.
Author's response
Our statement is based on previous studies, for example, please
refer to reference 9 for the role of PKC-β in BCR signaling.
4. To exclude the possibility of cross-hybridizations
amplifying PKC-b expression signals the authors could
check for the uniqueness of the probes to PKC-b on all of
the arrays (both cDNA and affymetrix).
Author's response
We agree with the reviewer. The issue has been addressed by
detailed discussion of probe sequences in Table 2and the
method section.
Minor Criticisms
Abstract:
1. We suggest that the sentence be changed to reflect the
gene expression from the microarrays – "Our analysis
showed that the level of PKC-b expression was..."
2. We suggest that the sentence specify the expression of
PKC-b – "...lymphoma (DLBCL), the level of PKC-b
expression was significantly..."
3. Given that the p-value is significant, it doesn't seem
necessary to also include it in a parenthetical reference.
Background:
1. To clarify the two PKC-b isoforms, it would be useful to
change the format to something similar to – "The PKC-b1
and -b2 isoforms..."
2. There is no citation for "Additionally VEGF-mediated
mitogenic effects were blocked by PKC-b inhibitor
LY333531, but not by antisense oligonucleotides to PKC-
a."
Results:Biology Direct 2007, 2:8 http://www.biology-direct.com/content/2/1/8
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1. To clarify that the subtypes are being listed, we suggest
using a colon after, "... among the three gene expression
DLBCL subtypes: germinal ..."
2. On figure 3A, it is difficult to see some of the lines, so
we suggest to bolden the Q3 lines.
3. On figure 3B, we suggest to make the PKC-b medium
line bolder.
4. On figure 3B, we suggest to change the x-axis to years
instead of months, to be consistent with the other graphs.
Also, for consistency, it might be nice to see it divided into
quartiles, instead of thirds.
5. On figure 5B, in all three plots, it is difficult to distin-
guish the Q3+Q4 line in the on-line version and would be
much easier to read if this line were darker
Discussion:
1. In the first sentence"know" to "understand."
2. There is no citation for, "Global gene expression analy-
sis with DNA microarray technology has proven to be a
useful tool for target identification and validation in both
the preclinical and clinical settings."
3. There is no citation for, "Gene expression analysis is
currently used for diagnosis, prognosis and therapeutic
decision-making in a variety of cancers."
4. Change "PKC-B" to "PKC-b"
5. Change from "drugable genes" to "genes that are poten-
tial drug targets."
6. Change to a colon after, "...clustered DLBCL patients
into three subtypes: GCB, ABC..."
7. There is no reference to figure 2 when it is mentioned
in, "Our analysis showed significantly higher PKC-b in the
ABC..."
8. The reference should be to Table 3, not Table 2, after,
"Gene annotation and pathway analyses presented in the
current report..."
Author's response
We have modified the manuscript to address every point in
reviewer's comments, except for the suggestion to change the
boldness of lines in Figure 3Band 5B. Since the figures were
generated using the software MedCalc (see the Method's sec-
tion), we could not modified each lines. However, since the
lines are in color, we feel the readers should be able to distin-
guish different survival curves that were represented by differ-
ent colors.
Reviewer's report 3
Dr. Matthew Coleman, Lawrence Livermore National
Labs, Livermore, CA 94550. Nominated by Dr. Sandrine
Dudoit.
Reject until major revisions are made. Scientific quality of
the work is high and should be of general interest once
major revisions are made. The paper would have been
strengthened by multiple statistical testing of the hypoth-
eses (see comments below). The tables and figures should
be restricted to those that are critical. All other figures/
tables should be moved to a supplemental data section.
General Comments for the Author:
The authors take a statistical and bioinformatics approach
to rexamine the role for protein kinase C-beta (PKC-b) in
tumor pathogenesis related to B-cell malignancies. They
reanalyzed global gene expression data to correlate gene
expression across diagnostic groups and than determined
associations between PKC-b expression and survival. The
paper is clearly written and the scientific data is very con-
vincing regarding PKC-b expression. However the discus-
sion/scientific impact only corroborate previous
expression studies on the role of multiple critical cellular
pathways such as anti-apoptosis, cell proliferation, and
signalling pathways, that were found to be loosely associ-
ated with PKC-b function. A more rigorous bioinformatics
study on the relationship between PKC-b expression and
the other pathways would have added impact to the study.
Multiple tools are available on the web for looking at co-
expression and pathway analysis and should be used to
strength the authors findings. Many of these tools would
also add significance the pathway/association analysis,
which was found missing from this study. The elevated
PKC-b levels tied to prognosis is an interesting finding
that should be of interest to the general readership.
Author's response
We appreciate that the reviewer pointed out "Scientific quality
of the work is high and should be of general interest" and "The
paper is clearly written and the scientific data is very convinc-
ing". We have made revisions to address reviewer's comments.
Similar to our response to the 2nd reviewer's report, we modified
the abstract and the discussion section to highlight the novelty
of the study. We have performed additional analysis to identify
genes with expressions highly correlated with PKC-β, followed
by mapping them to biological pathways. These analyses con-
firmed our results in Figure 6 and Table 3. Please see below for
detailed response to each of reviewer's specific comments.
Specific Comments:Biology Direct 2007, 2:8 http://www.biology-direct.com/content/2/1/8
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1. Genes not represented between two different popula-
tion and different array platforms or different analysis
algorithms should at have identify similar pathways if not
exact genes. (17 vs. 13 genes). Is this possible with your
findings? Also, the authors could reanalyze this data start-
ing from raw microarray data to see if similar algorithms
derive the same answer.
Author's response
The issue has been widely studied recently and it has been dem-
onstrated that even though different gene sets were used for
prognostication in cancer patients, they showed significant
agreement in the outcome predictions and are probably tracking
a common set of biologic phenotypes. Please see a recent publi-
cation on New England Journal of Medicine: Fan C, Oh DS,
Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ,
Perou CM. (2006) Concordance among gene-expression-based
predictors for breast cancer. N Engl J Med. 355(6):560-9. This
topic is beyond the scope of the current study.
2. How was the data sorted into quartiles? It appears arbi-
trary and not statistical as written. Would the use of super-
vised and unsupervised methods distinguish between the
same groupings of data and would these methods validate
the significance?
Author's response
In our study, we applied two approaches in analyzing the corre-
lation between PKC-β expression and patient survival. In one
approach, we used the Kaplan-Meier survival analysis after
grouping patients into 4 quartiles. We also applied Cox Propor-
tional-Hazards Regression model to analyze the same dataset
and reached the same conclusion. However, we only reported
the Kaplan-Meier analysis results in the original manuscript.
To address reviewer's concern, we added a sentence in the result
section to indicate that the Kaplan-Meier analysis results were
confirmed by the Cox Proportional-Hazards Regression model.
3. Table two should be moved to supplemental data
Author's response
We also considered the option of moving Table 2 to a supple-
mental file. However, in the 2nd reviewer's report, the reviewer
pointed out the importance of analyzing probe sequences in
both cDNA and Affymetrix array platforms to exclude the pos-
sibility of cross hybridization. Therefore, we feel it is necessary
to show our analysis and discussion of probe sequences in Table
2.
4. Table 3 gene list should be summarized to include sig-
nificance based on comparing to background array data.
The individual gene list could be moved to supplemental
data.
Author's response
Table 3 has been modified to only include gene categories. The
individual gene list has been moved into Additional file 1. The
main text has also been modified accordingly.
5. Figures 2, and 5A are not necessary.
Author's response
Figure 2 and 5A provide a direct visualization of the distribu-
tion of different PKC-β quartiles in DLBCL subtypes. We feel
that it is better to describe the results using both figures and
text.
6. Figure 4 is misaligned obscuring the y axis.
Author's response
We appreciate the reviewer pointed this out and it has been
fixed.
7. Graphs should be redone without color to better illus-
trate the data.
Author's response
As we discussed in response to the 2nd reviewer's report, the fig-
ures were generated using the software MedCalc (see the
Method's section). We feel the readers should be able to better
distinguish different survival curves that were represented by
different colors.
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